Literature DB >> 16264272

Alternative therapy of earth elements increases the chondroprotective effects of chondroitin sulfate in mice.

M Caraglia1, S Beninati, G Giuberti, A M D'Alessandro, A Lentini, A Abbruzzese, G Bove, F Landolfi, F Rossi, E Lampa, M Costantino.   

Abstract

The administration of mineral sulphur water is an alternative experimental approach for the treatment of rheumatic diseases, such as osteoarthritis (OA), that cause the degeneration of bone and cartilage and sufferance to the patients. Chondroitin sulfate (CS) is a symptomatic slow acting nutropeucital agent currently used in molecular therapy of OA. Therefore, we have studied the role and efficacy of the selective soil paste from the mineral sulphur enriched spring (mud)-therapy alone or in combination with CS in the treatment of OA. The study was performed on 40 C57 Black 6N mice, an experimental model which spontaneously develop an osteoarthritic process. The animals were divided in 4 groups and were treated with the single agents or with the combination. After 30 days of treatment all the mice were sacrificed and right knees and blood were collected. It was found that CS determined a reduction of radiological and histological features of chondrodegeneration and that mud-therapy increased the effects of CS in the animal group treated with the combination. However, the effects of thermal therapy alone were not statistically significant. Since OA is characterized by an increase of the production of nitric oxide (NO) by chondrocytes in extracellular matrix with its consequent elevation in serum and synovial fluid, we have evaluated the effects of the treatments on serum NO levels. CS alone induced a statistically significant reduction of NO serum levels (90+/-13 micromM vs 219+/-60 microM of control group, P<0.05) while mud-therapy alone induced a not statistically significant reduction of serum NO (170+/-62 microM, P>0.05). However, the latter strongly potentiated the decrease of serum NO induced by CS (31+/-1.5 microM) with a high statistical significance if compared to both the control group (P<0.01) and the CS-treated group (P<0.05). In conclusion, this study demonstrates that mud-therapy with sulphur mineral water could represent an important phase of the therapeutic strategy of OA. This experimental strategy could integrate and potentiate the standard pharmacological tools. Moreover, we have set a valid experimental in vivo model for the study of the thermal effects on the development of OA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16264272     DOI: 10.1038/emm.2005.58

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  5 in total

1.  Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations.

Authors:  Yves Henrotin; Mariane Mathy; Christelle Sanchez; Cecile Lambert
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

2.  Comparison of the ability of chondroitin sulfate derived from bovine, fish and pigs to suppress human osteoclast activity in vitro.

Authors:  M D Cantley; K D Rainsford; D R Haynes
Journal:  Inflammopharmacology       Date:  2013-05-04       Impact factor: 4.473

3.  Clinical Efficacy of Mudpack Therapy in Treating Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Studies.

Authors:  Jie Xiang; Dongying Wu; Jian'an Li
Journal:  Am J Phys Med Rehabil       Date:  2016-02       Impact factor: 2.159

4.  Evaluation of the Use of Sterilized and Non-Sterilized Peruibe Black Mud in Patients with Knee Osteoarthritis.

Authors:  Paulo Fávio Macedo Gouvêa; Zélia Maria Nogueira Britschka; Cristina de Oliveira Massoco Salles Gomes; Nicolle Gilda Teixeira de Queiroz; Pablo Antonio Vásquez Salvador; Paulo Sergio Cardoso Silva
Journal:  Int J Environ Res Public Health       Date:  2021-02-09       Impact factor: 3.390

5.  Immunological Events, Emerging Pharmaceutical Treatments and Therapeutic Potential of Balneotherapy on Osteoarthritis.

Authors:  Anna Scanu; Lucrezia Tognolo; Maria Chiara Maccarone; Stefano Masiero
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.